Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Sales, net	$ 13,098	$ 15,634	$ 37,678	$ 42,979
Cost of sales	12,090	13,652	34,603	37,823
Gross profit	1,008	1,982	3,075	5,156
Selling and administrative expenses	964	990	3,034	2,849
Operating income	44	992	41	2,307
Other income (expense), net
Interest expense	(13)	(30)	(38)	(104)
Realized loss on sale of investment in iBio Stock	0	0	(35)	0
Unrealized (loss) gain on investments	0	(6)	27	(48)
Other income, net	15	4	22	35
Other income (expense), net	2	(32)	(24)	(117)
Income before income taxes	46	960	17	2,190
Income tax (expense) benefit, net	(30)	(163)	(91)	154
Net income (loss)	$ 16	$ 797	$ (74)	$ 2,344
Basic earnings per common share (in dollars per share)	$ 0.00	$ 0.03	$ (0.00)	$ 0.08
Diluted earnings per common share (in dollars per share)	$ 0.00	$ 0.03	$ (0.00)	$ 0.07
Weighted average common shares outstanding - basic (in shares)	29,949,610	29,821,138	29,949,610	29,826,321
Add: Equivalent shares outstanding (in shares)	1,513,699	2,539,260	0	2,587,508
Weighted average common shares outstanding - diluted (in shares)	29,949,610	32,360,398	29,949,610	32,413,829